INTRODUCTIONIn the research setting, obtaining accurate established biomarker measurements and maximizing use of the precious samples is key. Accurate technologies are available for Alzheimer's disease (AD), but no platform can measure all the established and emerging biomarkers in one run. The NUcleic acid Linked Immuno‐Sandwich Assay (NULISA) is a technology that requires 15 µL of sample to measure more than 100 analytes.METHODSWe compared AD‐relevant biomarkers included in the NULISA against validated assays in cerebrospinal fluid (CSF) and plasma.RESULTSCSF measures of amyloid beta 42/40, and phosphorylated tau (p‐tau)217 are highly correlated when measured by immunoassay, mass spectrometry, or NULISA. In plasma, p‐tau217 performance is similar to that reported with other technologies when predicting amyloidosis. Other biomarkers show a wide range of correlation values depending on the fluid and the platform.DISCUSSIONThe NULISA multiplexed platform produces reliable results for established biomarkers in CSF that are useful in research settings, with the advantage of measuring additional biomarkers using minimal sample volume.Highlights We tested the novel technology NUcleic acid Linked Immuno‐Sandwich Assay (NULISA) in the dementia research setting. NULISA multiplexed platform produces reliable results for established and emerging biomarkers using minimal sample volume. Cerebrospinal fluid measures of amyloid beta 42/40, and phosphorylated tau (p‐tau)217 are highly correlated when measured by immunoassay, mass spectrometry, or NULISA. In plasma, p‐tau217 performance is similar to that reported with other technologies when predicting amyloidosis. NULISA measures are useful in research settings, with the advantage of measuring additional biomarkers using minimal sample volume.

中文翻译：

---

阿尔茨海默病和相关痴呆研究的多生物标志物低容量面板的基准


引言在研究环境中，获得准确、已建立的生物标志物测量值并最大限度地利用珍贵样本是关键。阿尔茨海默病 （AD） 有准确的技术，但没有一个平台可以一次性测量所有已建立和新出现的生物标志物。核酸联免疫夹心检测 （NULISA） 是一种需要 15 μL 样品来测量 100 多种分析物的技术。方法我们将 NULISA 中包含的 AD 相关生物标志物与脑脊液 （CSF） 和血浆中经过验证的检测进行了比较。结果通过免疫测定、质谱或 NULISA 测量时，淀粉样蛋白 β 42/40 和磷酸化 tau （p-tau）217 的 CSF 测量值高度相关。在血浆中，p-tau217 在预测淀粉样变性时的性能与其他技术报道的性能相似。其他生物标志物根据液体和平台显示出广泛的相关值。讨论NULISA 多重平台可为 CSF 中已建立的生物标志物提供可靠的结果，这些结果在研究环境中很有用，其优点是可以使用最少的样本量测量额外的生物标志物。亮点 我们在痴呆研究环境中测试了新技术 NUcleic acid Linked Immuno-Sandwich Assay （NULISA）。NULISA 多重平台使用最少的样品量为已建立和新兴的生物标志物提供可靠的结果。通过免疫测定、质谱或 NULISA 测定的脑脊液淀粉样蛋白 β 42/40 和磷酸化 tau （p-tau）217 的测量值高度相关。在血浆中，p-tau217 在预测淀粉样变性时的性能与其他技术报道的性能相似。 NULISA 测量在研究环境中很有用，其优点是可以使用最少的样品量测量额外的生物标志物。